ERBB2 and gastric cancer: FDA approval was given for the use of trastuzumab in HER2‐positive metastatic gastric cancers following the results of the ToGA trial, where median overall survival was 13.8 months in patients given trastuzumab with chemotherapy, compared to 11.1 months in those patients given chemotherapy alone 8.